Abstract 5914
Background
The case for investing in better integrated mental health provision and training in cancer care is compelling. Mental health co-morbidity in cancer and end of life care is very common, poorly recognized, and leads to distress and loss of functioning. The recent SMaRT oncology trials, (Walker et al., 2014) have demonstrated that up to 73% of cancer patients with depression receive no evidence-based treatment for their depression. Standardized mortality ratio (SMR) for completed suicide in the cancer patient is four to seven times that of the matched population, (Robinson et al., 2009; Robson et al ., 2010). The increased awareness of co-morbid mental health conditions have impacted upon and influenced the cancer world. Yet, despite the plethora of research and policy advocating for better mental health provision for cancer patients, there is still a lack of recognition of the importance of assessing and managing co-morbid mental health in cancer patients.
Methods
The authors designed a one-day simulation based training programme using trained actors portraying cancer journeys, from diagnosis to end of life, with a number of different and relevant mental health co-morbidities. Inter-professional participants (n = 75) filled questionnaires both before and after the intervention (the simulation programme). The questionnaires consisted of multiple choice questions assessing knowledge of mental health co-morbidity in the cancer patient, and confidence (self- rated 1-5 Likert scales).
Results
Statistical t test analysis of pre v post intervention scores (n = 75) revealed highly statistically significant imrpovements to participants’ clinical knowledge (p < 0.0001) and confidence (p < 0.0001) as a result of the simulation intervention.
Conclusions
This study demonstrates that an innovative simulation programme has been evaluated as highly effective in improving knowledge and confidence of inter-professional learners at managing mental health co-morbidity in cancer patients. More research in this educational modality is welcomed in training clinicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Fernando.
Funding
Health Education England.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract